---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-24-000207"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2024-07-01T23:59:59+00:00"
generated_at: "2026-06-01T00:19:24.541076+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Artivion provides $25M additional loans to Endospan, reduces purchase option to $135M net

## Summary
- Up to $25M in three tranches ($7M upfront) to fund NEXUS FDA approval; loan secured by first-priority lien.
- Purchase option upfront payment reduced from $250M to $175M; net to $135M after loan offset.
- $100M minimum earnout eliminated; earnout now 2.5x incremental year-2 revenue (max $200M).
- Company does not expect material impact on FY2024 guidance.

## SEC filing metadata
- accession: 0000784199-24-000207
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2024-07-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419924000207/0000784199-24-000207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419924000207/aort-20240701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-24-000207
- JSON: https://secwatch.observer/filing/0000784199-24-000207.json
- Plain text: https://secwatch.observer/filing/0000784199-24-000207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.